Compare HDSN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDSN | RLMD |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.2M | 319.7M |
| IPO Year | 1996 | 2012 |
| Metric | HDSN | RLMD |
|---|---|---|
| Price | $7.23 | $4.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.50 | $9.00 |
| AVG Volume (30 Days) | 195.4K | ★ 620.1K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.21 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $237,118,000.00 | $13,070.00 |
| Revenue This Year | $3.38 | N/A |
| Revenue Next Year | $2.96 | N/A |
| P/E Ratio | $13.18 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $5.11 | $0.24 |
| 52 Week High | $10.52 | $5.12 |
| Indicator | HDSN | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 52.37 |
| Support Level | $6.93 | $3.81 |
| Resistance Level | $7.65 | $4.56 |
| Average True Range (ATR) | 0.26 | 0.35 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 32.35 | 69.19 |
Hudson Technologies Inc is an American industrial products manufacturer. It develops products which are mainly used in commercial air conditioning, industrial processing, and refrigeration systems. The company products include refrigerant and industrial gases, refrigerant management services and RefrigerantSide services, which consist of system decontamination. These are performed at customer's site using its Zugibeast system, which is a fast and portable system and allows the R-Side services team to accelerate critical services while saving customers time, money and aggravation. The company also owns a web-based real-time monitoring service which is used in the facility's refrigeration systems and other energy systems.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.